Skip to main content
. 2023 Nov 21;110(2):956–964. doi: 10.1097/JS9.0000000000000912

Figure 1.

Figure 1

Multivariate Cox HR for OS and PFS in LS-SCEC. CT, chemotherapy; CT+RT, chemotherapy plus radiotherapy; CT+S, chemotherapy plus surgery; EP, etoposide plus cisplatin or carboplatin; HR, hazard ratio; KPS, Karnofsky performance status; LS-SCEC, limited-stage small cell esophageal carcinoma; OS, overall survival; PFS, progression-free survival.